undamentalytics Newsletter
Sign in

Gossamer Bio, Inc. income statement

In fiscal 2025, Gossamer Bio, Inc. reported revenue of $48.5m, down 57.7% on the year before, operating income of −$171m (a -352.2% margin) and net income of −$170m, or −$0.75 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue001154853
Research and development171135138174164
General and administrative4838363848
Operating income−219−184−60−171−166
Interest expense1414121111
Income before tax−229−180−56−170—
Income tax001−0—
Net income−229−180−57−170−125
Diluted EPS−$2.71−$1.18−$0.25−$0.75−$0.49
Diluted shares (average)85m153m226m229m256m
EBITDA−217−182−59−171−166

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GOSS vs SIGAGOSS vs TNGXGOSS vs OCULGOSS vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Gossamer Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gossamer Bio, Inc.